Medical Research
(H12)
IRS Verified
DX Registered
990 on File
PARTNERSHIP FOR CURES
Financial strength (30%)
80/100
Reliability (20%)
55/100
Effectiveness (25%)
83/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
Cures Within Reach improves patient quality and length of life by leveraging the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly. Cures is the philanthropic leader in drug, device and nutraceutical repurposing research, which has the potential to transform the lives of patients with unsolved diseases by delivering treatments that can be used in the near-term.
Financial Overview — FY 2025
$3.9M
Total Revenue
$1.3M
Total Expenses
$6.0M
Net Assets
4
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
86.3%
Fundraising Efficiency
57.8%
Operating Reserve
55.11x
Liability-to-Asset
19.8%
Revenue Diversification
91.6%
Executive Compensation
$212K
Compared with Peers
FY 2025
Compared with 132 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
86.3% | 83.0% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
8.6% | 9.9% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
5.1% | 2.6% |
P10P90
|
Below median |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
57.8% | 110.6% |
P10P90
|
Above median |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
55.1 mo | 14.4 mo |
P10P90
|
Top quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
19.8% | 13.2% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
91.6% | 90.0% |
P10P90
|
Below median |
|
Revenue growth
Year over year revenue growth
|
118.4% | 7.4% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
-18.5% | 3.0% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
66.2% | 4.8% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $3.9M | $1.3M | $6.0M | 86.3% | 4 |
| 2024 | $1.8M | $1.6M | $3.4M | 87.5% | 3 |
| 2023 | $2.2M | $1.3M | $3.2M | 88.5% | 3 |
| 2022 | $1.5M | $1.0M | $2.3M | 85.3% | 3 |
| 2021 | $2.1M | $1.3M | N/A | — | 3 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.